Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Terapia de procesamiento cognitivo asistida por psilocibina para el trastorno de estrés postraumático crónico

1 de octubre de 2026 actualizado por: Unity Health Toronto

Terapia de procesamiento cognitivo masivo asistida por psilocibina para el trastorno de estrés postraumático crónico: un ensayo abierto

This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.

Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

15

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ontario
      • Toronto, Ontario, Canadá, M5S 1A1
        • St. Michael's Hospital, Unity Health Toronto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;
  2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;
  3. Are willing to refrain from taking any psychiatric medications during the study period.

Exclusion Criteria:

  1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;
  2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;
  3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;
  4. Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions;
  5. History of seizure disorder;
  6. Uncontrolled insulin-dependent diabetes;
  7. Recent stroke, intracranial or subarachnoid hemorrhage (< 1 year from signing of informed consent form [ICF]), recent myocardial infarction (< 1 year from signing of ICF), clinically significant arrhythmia (< 1 year from signing of ICF);
  8. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;
  9. Lifetime history of substance-induced psychosis;
  10. Lifetime history of substance use disorder with a hallucinogen;
  11. History of alcohol use disorder in the past 3 months.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Experimental

Single dose of psilocybin 25mg + Massed cognitive processing therapy

Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Feasibility and tolerability
Periodo de tiempo: Up to 16 weeks

Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with severe adverse events.

Up to 16 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cuestionario de Trauma Infantil-forma corta (CTQ-SF)
Periodo de tiempo: Cribado
Cribado
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
Periodo de tiempo: Up to 16 weeks

The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms.

Up to 16 weeks
Posttraumatic stress disorder Checklist-5 (PCL-5)
Periodo de tiempo: Up to 16 weeks

The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD.

Up to 16 weeks
Patient Health Questionnaire-9 (PHQ-9)
Periodo de tiempo: Up to 16 weeks

The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe).

Up to 16 weeks
Generalized Anxiety Disorder Scale, 7-item (GAD-7)
Periodo de tiempo: Up to 16 weeks

Total score ranges from 0 to 21; a higher score denotes greater symptom severity.

Up to 16 weeks
Dissociative Experiences Scale II (DES-II)
Periodo de tiempo: Up to 13 weeks

The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences.

Up to 13 weeks
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: Up to 13 weeks

The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.

Up to 13 weeks
World Health Organization Well-Being Index, 5-item (WHO-5)
Periodo de tiempo: Up to 16 weeks

The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life.

Up to 16 weeks
Quality of relationships inventory (QRI)
Periodo de tiempo: Up to 13 weeks

The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true.

Up to 13 weeks
Inventory of psychosocial functioning (IPF)
Periodo de tiempo: Up to 13 weeks

The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days.

Up to 13 weeks
Posttraumatic Maladaptive Beliefs Scale (PMBS)
Periodo de tiempo: Up to 13 weeks

The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure.

Up to 13 weeks
Brief Experiential Avoidance Questionnaire (BEAQ)
Periodo de tiempo: Up to 13 weeks

The BEAQ is a 15-item self-report measure of experiential avoidance.

Up to 13 weeks
24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)
Periodo de tiempo: Up to 13 weeks

The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility.

Up to 13 weeks
Working Alliance Inventory- Short Form (WAI-SF)
Periodo de tiempo: Up to Day 7

The WAI-SF is a patient-rated measure of the alliance between a therapist and client.

Up to Day 7
Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)
Periodo de tiempo: Up to 13 weeks

The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults.

Up to 13 weeks
Self-Compassion Scale-Short Form (SCS-SF)
Periodo de tiempo: Up to 13 weeks

The SCS-SF is a 12-item self-report measure of self-compassion.

Up to 13 weeks
Psychological Insight Questionnaire (PIQ)
Periodo de tiempo: Up to Day 3

The PIQ is a 23-item self-report measure of acute experiences of insight (e.g. awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic.

Up to Day 3
Emotional Breakthrough Inventory (EBI)
Periodo de tiempo: Up to Day 3

The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state.

Up to Day 3
Altered States of Consciousness Rating Scale (ASC)
Periodo de tiempo: Up to Day 3

The ASC measures altered states of consciousness.

Up to Day 3
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
Periodo de tiempo: Up to Day 3

The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility.

Up to Day 3

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Effect on digital physiological passive data collected through the use of a wearable device
Periodo de tiempo: Up to 16 weeks

Example: sleep, activity

Up to 16 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de junio de 2026

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

18 de abril de 2024

Primero enviado que cumplió con los criterios de control de calidad

22 de abril de 2024

Publicado por primera vez (Actual)

26 de abril de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de octubre de 2026

Última verificación

1 de diciembre de 2025

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 23-230

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .